08 jun: Det bølgende hus
10 jun: Overskud i APM´s containerforretning
08-06-2012 23:55:00

J&J to Record $600 Million Charge in 2Q

Relateret indhold

Johnson & Johnson (JNJ) said it plans to record a special charge of roughly $600 million in its second quarter to increase its accrual for potential legal settlements, as it has faced a series of lawsuits over accusations of bribery and improper drug-marketing practices.

The company said the settlement payments stem for a series of outstanding civil cases that involve its drugs Risperdal, Invega and Natrecor, as well as nursing-home pharmacy operator Omnicare Inc. (OCR).

The health-care products company has faced lawsuits related to alleged off-label promotion of its antipsychotic treatment Risperdal, which was once J&J's top-selling drug before generic copycats hit the market, as well as legal challenges over off-label promotion of another schizophrenia treatment, Invega, and the heart-failure drug Natrecor.

Furthermore, the federal government is suing J&J, accusing it of paying kickbacks to induce Omnicare to encourage use of Risperdal and other J&J drugs.

In addition, J&J has dealt with state lawsuits regarding its promotion of Risperdal, including an Arkansas case in which the company in April was ordered to pay $1.2 billion after a jury found that J&J's past marketing of the drug violated the state's consumer-protection laws. J&J previously was ordered to pay $327 million in a South Carolina case and $258 million in Louisiana. The company is appealing all three cases.

In January, J&J agreed to settle a Texas case for $158 million.

Meanwhile, the company agreed to pay an $85 million fine in a criminal case regarding off-label marketing of Natrecor. Parallel civil litigation still hasn't been settled.

The company in April said its first-quarter earnings rose on a foreign-exchange-related gain tied to an acquisition and lower expenses.

Shares closed Friday at $62.98 and were unchanged after hours. The stock is down 4% so far this year.

Write to Ben Fox Rubin at ben.rubin@dowjones.com

(END) Dow Jones Newswires

June 08, 2012 17:55 ET (21:55 GMT)

Copyright (c) 2012 Dow Jones & Company, Inc.

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Fondsbørsmeddelelser

Formuepleje køber igen teleaktier: Flere års nedtur giver muligheder

23-11-2017 15:32:39
Fra tidligere ikke at have villet røre teleaktier med en ildtang er Formuepleje vendt rundt og har nu flere selskaber i porteføljen.Teleselskaberne har gennem flere år været udfordret af hård konkurrence, lave priser og et tungt investeringsbehov, hvilket har gjort sektoren upopulær blandt investorerne på aktiemarkedet.På det seneste er den udvikling dog vendt, og de seneste to-tre uger har telese..

Vestas/HSBC: Lavere prisforudsætninger bag hug på 22 pct. i kursmålet

23-11-2017 13:34:01
Vindindustrien oplever markedsturbulens og prispres på vindmøller, hvilket har fået storbanken HSBC til at skære kraftigt i kursmålene for selskaber som Vestas, Siemens Gamesa og Nordex.- Prispresset er intensiveret og påvirker marginerne for alle vindmølleproducenter. Vi venter, at det negative momentum vil fortsætte, indtil der kommer tegn på en stabilisering af priserne under auktionssystemerne..

Aktier/middag: Vestas-nedtur for femte dag i træk tynger C20

23-11-2017 11:33:16
Der er en overvægt af røde aktier på det danske aktiemarked torsdag, hvor særligt Vestas og FLSmidth er ramt af udsalg, mens Royal Unibrew bliver belønnet for sit regnskab for tredje kvartal.Omkring 11.30-tiden falder det toneangivende C20 Cap-indeks 0,5 pct. til 1115,75. Aktiviteten er påvirket af, at de amerikanske børser holder lukket som følge af thanksgiving.For femte dag i træk dykker Vestas..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Vestas i laveste niveau i over to år
2
Torsdagens aktier: Vestas' november-nedtur fik et nyt kapitel - NY
3
Pandora: Amerikanere øger spekulation i kursfald
4
Fingerprint Cards: Rygter om kinesisk bud sætter skub i aktien
5
Vestas/HSBC: Lavere prisforudsætninger bag hug på 22 pct. i kursmålet

Relaterede aktiekurser

Johnson & Johnson 137,29 0,0% Aktiekurs uændret

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2017  Disclaimer Privatlivspolitik
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
23. november 2017 21:28:57
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20171123.3 - EUROWEB7 - 2017-11-23 21:28:57 - 2017-11-23 21:28:57 - 1 - Website: OKAY